CD274 and neoplasm: In addition to known predictive biomarkers of clinical benefit from immunotherapy, such as PDL1 expression and DNA mismatch repair (MMR) alterations, newer biomarkers such as high tumor mutational burden (TMB)34,35 may prove useful in TNBC.